A new Phase 4 clinical trial involving lixisenatide, as part of the combination iGlarLixi, is now recruiting participants, according to a trial update dated July 7, 2026. The study is titled "Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents."
The trial is registered under identifier NCT07307235 and is listed as Phase 4. Its current status is recruiting, meaning enrollment of participants is underway or open.
The study is designed to compare iGlarLixi, a combination product containing lixisenatide, against standard of care treatment. The target population consists of adult patients in China with type 2 diabetes that remains uncontrolled despite treatment with oral agents.
No results, efficacy data, or safety outcomes have been posted for this trial as of the date of this update. The trial record reflects only the recruiting status and study design details at this stage.
Lixisenatide is an approved compound. This update reflects only the trial's recruitment status as registered on ClinicalTrials.gov and does not represent findings or conclusions about the treatment's effects.
Readers can consult the compound overview for additional background on lixisenatide.